PQR 309

Drug Profile

PQR 309

Alternative Names: PQR-309

Latest Information Update: 02 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PIQUR Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Lymphoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Glioblastoma; Lymphoma
  • Phase I/II Breast cancer
  • Phase I Solid tumours
  • Preclinical Brain disorders; Eye disorders; Skin cancer; Skin disorders

Most Recent Events

  • 27 Apr 2017 PQR 309 receives Orphan Drug status for Diffuse large B cell lymphoma in European Union
  • 27 Apr 2017 PQR 309 receives Orphan Drug status for Lymphoma (Primary CNS lymphoma) in USA prior to April 2017
  • 21 Apr 2017 PIQUR Therapeutics plans a phase II trial for CNS cancer (Second-line therapy or greater, Refractory metastatic disease) in France (NCT03120000)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top